X-Rays from the Nearby Solitary Millisecond Pulsar PSR J0030+0451 - the Final ROSAT Observations

We report on X-ray observations of the solitary 4.8 ms pulsar PSR J0030+0451. The pulsar was one of the last targets observed in DEC-98 by the ROSAT PSPC. X-ray pulses are detected on a $4.5\sigma$ level and make the source the $11^{th}$ millisecond pulsar detected in the X-ray domain. The pulsed fraction is found to be $69\pm18$. The X-ray pulse profile is characterized by two narrow peaks which match the gross pulse profile observed at 1.4 GHz. Assuming a Crab-like spectrum the X-ray flux is in the range $f_x= 2-3\times 10^{-13}$ erg s$^{-1}$ cm$^{-2}$ ($0.1-2.4$ keV), implying an X-ray efficiency of $L_x/\dot{E}\sim 0.5-5 \times 10^{-3} (d/0.23 {kpc})^2$.Comment: Accepted for publication in Ap

Will availability of inhaled human insulin (Exubera (R)) improve management of type 2 diabetes? The design of the Real World trial

Background: Common deterrents to insulin therapy for both physicians and patients are the complexity and burden of daily injections. In January 2006, the first inhaled human insulin (INH, Exubera(R) (insulinhuman [ rDNA origin]) InhalationPowder) was approved for use in adult patients with type 1 diabetes mellitus (T1DM) or type 2 diabetes mellitus (T2DM) in the United States and European Union. Results from the INH clinical trial program have shown comparable efficacy of INH to subcutaneous (SC) insulin and superior efficacy versus oral antidiabetic agents; thus providing effective glycemic control in adult patients with T2DM without the requirement for preprandial injections. However, because subjects in those trials were randomized to either INH or an alternative, the studies could not estimate the effect of INH on patient acceptance of insulin therapy. Therefore, traditional study designs cannot provide answers to important and practical questions regarding real world effectiveness, which is influenced by psychological and other access barriers.Methods: To overcome these limitations, the Real World Trial was designed to estimate the effect of the availability of INH as a treatment option for glycemic control. A total of approximately 700 patients from Canada, France, Germany, Italy, Spain, United Kingdom, and the United States with T2DM poorly controlled by oral agent therapy will be randomized to two different treatment settings. Patients and clinicians in both groups ( A & B) may choose from all licensed therapies for diabetes including SC insulin delivered by pens; INH will be an additional treatment option only available in Group A. The Real World Trial ( Protocol A2171018) has been registered with ClincalTrials. gov, registration id NCT00134147.Results: The primary outcome for the trial will be the difference in mean glycosylated hemoglobin (HbA(1c)) at 6 months between groups. The design was based on a preceding feasibility study examining the theoretical effects of inhaled insulin availability on treatment choice in 779 patients. In that study, patients were three times more likely to choose insulin therapy when inhaled insulin was available.Conclusion: Innovations in study designs may provide an opportunity to reveal unbiased answers to important treatment questions that are more relevant to prescribers, funding agencies, and healthcare policymakers

Fermion masses in the economical 3-3-1 model

We show that, in frameworks of the economical 3-3-1 model, all fermions get masses. At the tree level, one up-quark and two down-quarks are massless, but the one-loop corrections give all quarks the consistent masses. This conclusion is in contradiction to the previous analysis in which, the third scalar triplet has been introduced. This result is based on the key properties of the model: First, there are three quite different scales of vacuum expectation values: \om \sim {\cal O}(1) \mathrm{TeV}, v \approx 246 \mathrm{GeV} and $u \sim {\cal O}(1) \mathrm{GeV}$. Second, there exist two types of Yukawa couplings with different strengths: the lepton-number conserving couplings $h$'s and the lepton-number violating ones $s$'s satisfying the condition in which the second are much smaller than the first ones: $s \ll h$. With the acceptable set of parameters, numerical evaluation shows that in this model, masses of the exotic quarks also have different scales, namely, the $U$ exotic quark ($q_U = 2/3$) gains mass $m_U \approx 700$ GeV, while the D_\al exotic quarks (q_{D_\al} = -1/3) have masses in the TeV scale: m_{D_\al} \in 10 \div 80 TeV.Comment: 20 pages, 8 figure

Active Learning Techniques to Build Problem Solving Skills in Chemistry Students

Through the introduction of Team-Based Learning problem classes and a ‘Purple Pens’ feedback intervention in which students write their own feedback on a mixed formative and summative class test we have been able to observe a significant increase in exam performance in Foundation Year students. Both Science and Health students improved their exam performance by 13% and 11% respectively and both interventions were positively received by students

Hierarchical reinforcement learning as creative problem solving

publisher: Elsevier articletitle: Hierarchical reinforcement learning as creative problem solving journaltitle: Robotics and Autonomous Systems articlelink: http://dx.doi.org/10.1016/j.robot.2016.08.021 content_type: article copyright: © 2016 Elsevier B.V. All rights reserved

Molybdenum Disulfide Catalytic Coatings via Atomic Layer Deposition for Solar Hydrogen Production from Copper Gallium Diselenide Photocathodes

We demonstrate that applying atomic layer deposition-derived molybdenum disulfide (MoS2) catalytic coatings on copper gallium diselenide (CGSe) thin film absorbers can lead to efficient wide band gap photocathodes for photoelectrochemical hydrogen production. We have prepared a device that is free of precious metals, employing a CGSe absorber and a cadmium sulfide (CdS) buffer layer, a titanium dioxide (TiO2) interfacial layer, and a MoS2 catalytic layer. The resulting MoS2/TiO2/CdS/CGSe photocathode exhibits a photocurrent onset of +0.53 V vs RHE and a saturation photocurrent density of -10 mA cm-2, with stable operation for >5 h in acidic electrolyte. Spectroscopic investigations of this device architecture indicate that overlayer degradation occurs inhomogeneously, ultimately exposing the underlying CGSe absorber

Tacrolimus in pediatric renal transplantation

Tacrolimus was used as the primary immunosuppressive agent in 69 pediatric renal transplantations between December 17, 1989, and June 30, 1995. Children undergoing concomitant or prior liver and/or intestinal transplantation were excluded from analysis. The mean recipient age was 10.3±5.0 years (range, 0.7-17.5 years). Seventeen (24.6%) children were undergoing retransplantation, and six (8.7%) had a panel reactive antibody level of 40% or higher. Thirty-nine (57%) cases were with cadaveric kidneys, and 30 (43%) were with living donors. The mean donor age was 28.0±14.7 years (range, 1.0-50.0 years), and the mean cold ischemia time for the cadaveric kidneys was 27.0±9.4 hr. The antigen match was 2.7±1.2, and the mismatch was 3.1±1.2. All patients received tacrolimus and steroids, without antibody induction, and 26% received azathioprine as well. The mean follow-up was 32±20 months. One- and 4-year actuarial patient survival rates were 100% and 95%. One- and 4-year actuarial graft survival rates were 99% and 85%. The mean serum creatinine level was 1.2±0.8 mg/dl, and the calculated creatinine clearance was 82±26 ml/min/1.73 m2. The mean tacrolimus dose was 0.22±0.14 mg/kg/day, and the level was 9.5±4.8 ng/ml. The mean prednisone dose was 2.1±4.9 mg/day (0.07±0.17 mg/kg/day), and 73% of successfully transplanted children were off prednisone. Seventy-nine percent were not taking any antihypertensive medications. The mean serum cholesterol level was 158±54 mg/dl. The incidence of delayed graft function was 4.3%. The incidence of rejection was 49%, and the incidence of steroid-resistant rejection was 6%. The incidence of rejection decreased to 27% in the most recent 26 cases (January 1994 through June 1995). The incidence of new-onset diabetes was 10.1%; six of the seven affected children were able to be weaned off insulin. The incidence of cytomegalovirus disease was 13%, and that of posttransplant lymphoproliferative disorder was 10%; the incidence of posttransplant lymphoproliferative disorder in the last 40 transplants was 5% (two cases). All of the children who developed posttransplant lymphoproliferative disorder are alive and have functioning allografts. Based on this data, we believe that tacrolimus is a superior immunosuppressive agent in pediatric renal transplant patients, with excellent short- and medium-term patient and graft survival, an ability to withdraw steroids in the majority of patients, and, with more experience, a decreasing rate of rejection and vital complications

FK506 IN PEDIATRIC KIDNEY-TRANSPLANTATION - PRIMARY AND RESCUE EXPERIENCE

Between December 14, 1989, and December 17, 1993,43 patients undergoing kidney transplantation alone at the Children’s Hospital of Pittsburgh received FK506 as the primary immunosuppressive agent. The mean recipient age was 10.2 ± 4.8 years (range 0.7–17.4), with 7 (16%) children under 5 years of age and 2 (5%) under 2 years of age. Fifteen (35%) children underwent retransplantation, and 5 (12%) had a panel reactive antibody level greater than 40%. Twenty-two (51%) cases were with cadaveric donors, and 21 (49%) were with living donors. The mean follow-up is 25 ± 14 months. There were no deaths. One and three year actuarial graft survival was 98% and 85%. The mean serum creatinine and BUN were 1.2 ± 0.6 mg/dl and 26 ± 11 mg/dl; the calculated creatinine clearance was 75 ± 23 ml/min/1.73 m(2). Twenty-four (62%) patients have been successfully withdrawn from steroids, and 24 (62%) require no anti-hypertensive medication. Improved growth was seen, particularly in pre-adolescent children off steroids. Between July 28, 1990, and December 2, 1993, 24 children were referred for rescue therapy with FK506, 14.6 ± 16.4 months (range 1.1–53.2) after transplantation. Nineteen (79%) were referred because of resistant rejection; 4 (17%) were referred because of proteinuria; 1 (4%) was switched because of steroid-related obesity. There were no deaths. One and two year graft survival was 75% and 68%. Seventeen (71%) patients were successfully rescued, including 1 of 2 patients who arrived on dialysis. Four (24%) of the successfully rescued patients were weaned off steroids. While not without side effects, which include nephrotoxicity, neurotoxicity, diabetogenicity, and viral complications, FK506 appears to be an effective immunosuppressive agent for both primary and rescue therapy after kidney transplantation. Its steroid-sparing qualities may be of particular importance in the pediatric population